| 查看: 778 | 回复: 16 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
英语翻译
|
|||
|
Dose response studies The Applicant has presented two phase 2 studies for the claimed indications (for cSSTI: Study 200 and for cIAI: Study 202). Study 200 was a randomized, open-label, comparison study of hospitalized subjects with complicated Skin and Soft Tissue infections in which 160 patients received either tigecycline 25 or 50 mg twice daily with an initial dose of 50 or 100 mg, respectively. The clinical data from this study indicated a trend toward a dose-related clinical cure response (67% and 74%, respectively) and dose-related pathogen eradication (56% and 70%). Also dose-safety relationships appeared evident for the adverse events (AEs) of nausea (22% and 35%) and vomiting (13% and 18%). Since tigecycline is intended for use in complicated infections, efficacy was favoured in benefit/risk -balance, and the greater dosage schedule (50 mg twice daily with an initial dose of 100 mg) was used in all consecutive clinical Phase II and III trials. Study 202 was a phase 2, multicenter, open-label study in hospitalized subjects with complicated intra-abdominal infections in which 111 subjects received an initial IV loading dose of 100 mg of tigecycline followed by 50 mg every 12 hours. Treatment continued for at least 5 days but not more than 14 days. There were no comparator or placebo groups. Overall, it appears that the choice of the dosage regimen for phase 3 studies is based on pharmacokinetic considerations as well as tolerability. The safety profile in these phase 2 studies is consistent with that seen in the larger database of phase 3 clinical trials. However, it should be highlighted that one case of Clostridium difficile associated colitis has been reported in Study 202. Apparently, this was the only one serious case reported of this adverse event for subjects in Phase 2 and 3 trials. Complicated intra-abdominal infections (cIAI) Methods Two pivotal phase 3 trials (studies 301 and 306) have been submitted in support of the indication complicated intra-abdominal infections. Study 301 was carried out in the Western hemisphere, and 306 in worldwide. The study protocols were similar in all essential points. Both phase 3 were multicenter, double-blind (third-party unblinded) studies in which 1568 hospitalised patients (approximately 800 patients per trial) with complicated intra-abdominal infections who were candidates for or had received a laparotomy, laparoscopy, or percutaneous drainage of an intraabdominal abscess were randomized. Key inclusion criteria were the followings: 1. Hospitalized male or female subjects, at least 18 years of age. 2. Candidate for, or had, a laparotomy, laparoscopy, or percutaneous drainage of an intra-abdominal abscess. 3. Complicated intra-abdominal infection, such as: a. An intra-abdominal abscess. b. An intra-abdominal abscess (including liver and spleen) that developed in a postoperative subject who received more than 48 hours but not more than 5 days of a nonstudy antibiotic and an intraabdominal culture was obtained from the infected site. c. Appendicitis complicated by perforation (grossly visible) and abscess or periappendicular abscess. d. Perforated diverticulitis complicated by abscess formation or faecal contamination. e. Complicated cholecystitis with evidence of perforation or empyema. f. Perforation of the large or small intestine with abscess or fecal contamination. g. Purulent peritonitis or peritonitis associated with faecal contamination. h. Gastric or duodenal ulcer perforation with symptoms lasting at least 24 hours before operation. i. Traumatic bowel perforation with symptoms lasting at least 12 hours before operation. 4. No more than 1 dose of an antibiotic (single broad-spectrum agent or 1 dose of each antibiotic in a combination regimen such as metronidazole, ampicillin,gentamicin) after the baseline intra-abdominal culture was obtained from the infected site. [ Last edited by 痴夷子皮 on 2011-1-10 at 13:07 ] |
回复此楼» 猜你喜欢
材料工程085601，270求调剂
已经有24人回复
-
085404 293求调剂
已经有3人回复
-
调剂
已经有21人回复
-
复试调剂，一志愿郑州大学材料与化工289分
已经有15人回复
-
08工科求调剂290分
已经有12人回复
-
286求调剂
已经有16人回复
-
材料类284调剂
已经有24人回复
-
考研调剂-材料类-284
已经有14人回复
-
327求调剂
已经有11人回复
-
一志愿985初试354分生物调剂
已经有3人回复
» 抢金币啦！回帖就可以得到:
-
河北大学招收生物与医药专业调剂考生
+1/758
-
沈阳化工大学环境学院生物与医药、药学、化学、安全工程、环境工程等可调剂,名额充裕
+1/586
-
延安大学接收化学与化工学院接收调剂生（化学、化工学硕和材料与化工专硕）
+2/142
-
上海交通大学-宁波东方理工大学联培博士2026年秋季招生
+1/91
-
南京林业大学的土木工程是咋回事？
+1/90
-
四川农业大学（211和双一流）土木学院2026年市政工程（学硕）调剂2名
+1/90
-
华侨大学 材料专业 接收考研调剂
+1/88
-
河北大学招收生物与医药专业调剂考生
+5/75
-
延安大学国家级高层次人才团队招收材料、化学、化工相关领域调剂研究生数名
+1/41
-
西交利物浦大学黄彪院士招收26年全奖博士生1名（工业系统数字孪生方向）
+1/40
-
大同大学物理学专业硕士研究生招收调剂生
+1/35
-
山东理工大学资源与环境工程学院招收调剂考生
+1/19
-
C13、N15稳定同位素标记植物，助力科研人高效开展试验
+1/13
-
中国石油大学（北京）理学院2026年硕士研究生接收调剂生：物理、化学、材料等
+1/11
-
★上海★上海工程技术大学·环境与资源创新中心（ICER）接收化工材料环境等学科调剂生
+1/11
-
中科大科学岛分院2026年工程博士申请考核制-博士招生，4月10日截止
+1/8
-
招聘二次电池方向博士
+1/7
-
广东医科大学（东莞松山湖校区）生物医学工程学术型硕士接收调剂！
+1/6
-
Top-88悉尼科技大学数据科学/AI 招收2027年入学 校奖 博士生1到2名(国际和本地学生）
+1/5
-
徐工-环境工程学院-招收调剂硕士
+1/4
痴夷子皮(金币+10):谢谢 2011-01-12 13:46:26
痴夷子皮(金币+5):谢谢 2011-01-12 13:47:35
痴夷子皮(金币+5):谢谢 2011-01-12 13:47:35
|
. No more than 1 dose of an antibiotic (single broad-spectrum agent or 1 dose of each antibiotic in a combination regimen such as metronidazole, ampicillin,gentamicin) after the baseline intra-abdominal culture was obtained from the infected site. 感染引起腹腔内脓肿后只使用一种抗生素（单一的广谱药或超过联合用药中的一种抗生素 ，如甲硝唑，氨苄青霉素，庆大霉素） |
16楼2011-01-12 12:11:32
5楼2011-01-10 13:31:48
6楼2011-01-10 13:37:57
7楼2011-01-10 13:40:17
